Dyadic International, Inc. (DYAI)
| Previous Close | 1.5100 |
| Open | 1.5000 |
| Bid | 1.0600 x 200 |
| Ask | 1.9800 x 200 |
| Day's Range | 1.5000 - 1.5000 |
| 52 Week Range | 1.1900 - 2.4000 |
| Volume | |
| Avg. Volume | 23,512 |
| Market Cap | 43.461M |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2400 |
| Earnings Date | May 08, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Insider MonkeyDyadic International, Inc. (NASDAQ:DYAI) Q4 2023 Earnings Call Transcript
Dyadic International, Inc. (NASDAQ:DYAI) Q4 2023 Earnings Call Transcript March 28, 2024 Dyadic International, Inc. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were $-0.07. DYAI isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good evening, and welcome […]
- Thomson Reuters StreetEvents
Q4 2023 Dyadic International Inc Earnings Call
Q4 2023 Dyadic International Inc Earnings Call
GlobeNewswireDyadic Reports 2023 Full Year Results and Recent Company Progress
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein receptor binding domain (RBD) booster vaccine candidate for protection against COVID-19 infection Entered into several fully funded vaccine and antibody projects covering more than twelve targets since announcing topline clinical safety d
